2021         De Marchi F, Munitic I, Amedei A, Berry JD, Feldman EL, Aronica E, Nardo G, Van Weehaeghe D, Niccolai E, Prtenjaca N, Sakowski SA, Bendotti C, Mazzini L. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience and Biobehavioral Reviews127, 958-978.

2020         Prtenjača N, Dominović M, Peradinović J, Šajn R, Markovinović A, Munitić I. Optineurin Dysfunction in Amyotrophic Lateral Sclerosis: Why So Puzzling?, Periodicum BiologorumV121–122, No 1–2, 23–34, 2020

https://hrcak.srce.hr/ojs/index.php/periodicum_biologorum/article/view/10627

2020          Béland LC, Markovinovic A, Jakovac H, De Marchi F, Bilic E, Mazzini ​L, Kriz J, Munitic I. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune response. Brain Communications, 2,  fcaa124.

https://academic.oup.com/braincomms/article/2/2/fcaa124/5892251

2019          Smith AM, Buss F, Munitic, I. Editorial: The Role of Optineurin in Immunity and Immune-Mediated Diseases. Frontiers in Immunology 10, 2803.

https://www.frontiersin.org/articles/10.3389/fimmu.2019.02803/full

2019          Ban, J, Sámano C, Mladinic M, Munitic, I. Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets. Croatian Medical Journal 60, 109-120.

https://repository.biotech.uniri.hr/islandora/object/biotechri:339

2019          Hancevic, M, Bilic H, Sitas D, Pavlisa G, Borovecki F, Munitic I, Bilic E.  Attenuation of ALS progression during pregnancy—lessons to be learned or just a coincidence? Neurological Sciences, 40:1275-1278.

https://link.springer.com/article/10.1007%2Fs10072-019-03748-z

2018          Markovinovic A, Ljutic T, Beland LC, Munitic I. Optineurin Insufficiency Disbalances Proinflammatory and Anti-inflammatory Factors by Reducing Microglial IFN-beta Responses. Neuroscience 388:139–151.

2017          Markovinovic A, Cimbro R, Ljutic T, Kriz J, Rogelj B and Munitic I. Optineurin in amyotrophic lateral sclerosis: Multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms. Progress in Neurobiology, 154, 1-20.

2017          Malatesti N, Munitic I, and Jurak I. Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents. Biophysical Reviews, 9(2), 149-168.

2016           Pourcelot M, Zemirli N, Silva Da Costa L, Loyant R, Garcin D, Vitour D, Munitic I, Vazquez A, and Arnoult, D. The Golgi apparatus acts as a platform for TBK1 activation after viral RNA sensing. BMC Biology, 14, 69.

https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-016-0292-z

2016          Meena NP, Zhu G, Mittelstadt PR, Giardino Torchia ML, Pourcelot M, Arnoult D, Ashwell JD and Munitic I. The TBK1-binding domain of optineurin promotes type I interferon responses. FEBS Letters 590, 1498-1508.

https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.12176

2015          Li CC, Munitic I, Mittelstadt PR, Castro E, Ashwell JD. Suppression of dendritic cell-derived IL-12 by endogenous glucocorticoids is protective in LPS-induced sepsis. PLOS Biology, 13, e1002269.

https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002269

2015          Giardino Torchia ML, Munitic I, Castro E, Herz J, McGavern DB, Ashwell JD*. c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8 memory T-cell survival. European Journal of Immunology, 45, 2672-82.  

https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201445342

2013            Munitic I, Giardino Torchia ML, Meena NP, Zhu G, Li CC, Ashwell JD*. Optineurin Insufficiency Impairs IRF3 but not NF-kB Activation in Immune Cells. Journal of Immunology,  191(12), 6231-40.

https://www.jimmunol.org/content/191/12/6231.long